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Abstract While the human immunodeficiency virus (HIV)
epidemic was initially characterized by a high prevalence of
severe and widespread neurological pathologies, the develop-
ment of better treatments to suppress viremia over years and
even decades has mitigated many of the severe neurological
pathologies previously observed. Despite effective treatment,
mild neurocognitive impairment and premature cognitive ag-
ing are observed in HIV-infected individuals, suggesting a
changing but ongoing role of HIV infection in the central
nervous system (CNS). Although current therapies are effec-
tive in suppressing viremia, they are not curative and patients
must remain on life-long treatment or risk recrudescence of
virus. Important for the development and evaluation of a cure
for HIVwill be animal models that recapitulate critical aspects
of infection in vivo. In the following, we seek to summarize
some of the recent developments in humanized mouse models
and their usefulness in modeling HIV infection of the CNS
and HIV cure strategies.
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Introduction
Infection with human immunodeficiency virus (HIV), the un-
derlying cause of acquired immune deficiency syndrome
(AIDS), results in system-wide manifestations of disease.
The central nervous system (CNS) is one of the affected sys-
tems, and in the absence of treatment, infection can result in
severe brain pathology and cognitive/behavioral abnormalities.
These neurological deficiencies are grouped under the umbrel-
la term of HIV-1-associated neurocognitive disorders
(HAND). Effective treatment of HIV with combination antire-
troviral therapy (cART) has led to a decrease in the frequency
of severe HAND (HIV-associated dementia or HAD) from 10–
15 to 2% (Heaton et al. 2010). However, asymptomatic forms
of HAND exist and HIV infection is associated with premature
cognitive aging, despite effective cART (Cohen et al. 2015).
The asymptomatic form of HAND, termed asymptomatic
neurocognitive impairment (ANI), is included for research pur-
poses but not clinical diagnosis, and is detected via direct neu-
ropsychological assessment (Heaton et al. 2010).
The recent and dogma-redefining discovery that the brain
has a lymphatic system, consisting of lymphatic vessels adja-
cent to the dura that empty into the periphery (Aspelund et al.
2015; Louveau et al. 2015), suggests that better systems to
study the interactions between the CNS and peripheral im-
mune system will be key to modeling HIV infection in the
brain. A better understanding of the mechanisms involved in
viral trafficking and cART penetration into the brain and
whether or not the brain represents a tissue reservoir of HIV
that cannot be cleared with cART (or where HIV persists
despite prolonged cART) is all important for developing more
effective treatments to target HIV infection in the CNS.
Humanized mouse models
Mice that are reconstituted with human cells offer a unique
small animal model for studying HIV infection, as all strains
of mice are refractory to HIV infection. Humanized mice are
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created by implanting human tissues and/or injecting human
cells into various strains of immunodeficient mice (Fig. 1);
these animals have been extensively used successfully to
study HIV pathogenesis, transmission, and persistence
in vivo.
SCID-HIVE model To determine whether or not HIV-
infected cells directly contribute to HIV-associated encephali-
tis (HIVE), HIV-infected human myeloid cells have been di-
rectly injected into the brains of severe combined immune
deficient (SCID) mice, which lack murine B and T cells
(Tyor et al. 1993; Persidsky and Gendelman 1997; Persidsky
et al. 1996, 1997, 1999). This direct injection model results in
pathologic changes in about a week; pathology includes
encephalitis, astrogliosis (activated astrocytes), and increased
levels of mononuclear phagocyte trafficking.
Recently, this model has been used to investigate strategies
to mitigate HIV-induced inflammation in the CNS. CEP-
1347, an inhibitor of mixed multilineage kinases, has shown
promise in animal models of Huntington’s disease (Apostol
et al. 2008; Conforti et al. 2008). CEP-1347 has also been
shown to reduce microglia inflammation in vitro (Lund et al.
2005). In SCID-HIVEmice, CEP-1347 was able to reduce the
levels of microglia activation (microgliosis), as measured by
decreases in Iba-1 expression (Eggert et al. 2010). An IFN-
alpha inhibitor, B18R, was shown to effectively cross the
blood-brain barrier (BBB) and was able to resolve some of
the pathologies present in the SCID-HIVE model (Fritz-
French et al. 2014). Decreased presence of mouse
Fig. 1 Schematic of humanized mouse models for evaluating NeuroHIV
infection and/or cure strategies. The name of each model is followed by
the human cells/tissues and immunodeficient mouse strains used in the
generation of each type of humanized mouse. Brief description of
advantages and disadvantages of each model is listed
mononuclear phagocytes, decreased expression of IFN-
stimulated genes (ISGs), and decreased levels of mouse
microtubule-associated protein-2 (MAP-2) were noted in
B18R-treated mice, compared with untreated SCID-HIVE
mice. However, the levels of astrogliosis were unaffected in
mice treated with B18R, which remained significantly higher
than those seen in mice injected with uninfected cells. A Jak/
STAT inhibitor, ruxolitnib, was also evaluated for its ability to
reduce HIV-associated inflammation in the SCID-HIVE mod-
el (Haile et al. 2016). Dosing with ruxolitnib (20 or 50 mg/kg
twice per day) was able to significantly reduce astrogliosis in
treated mice, as measured by a reduction in glial fibrillary
acidic protein (GFAP) expression.
A number of the pathologies associated with the SCID-
HIVE model are mitigated or reduced in the presence of
cART (Cook et al. 2005; Cook-Easterwood et al. 2007;
Koneru et al. 2014), including astrogliosis, mononuclear cell
infiltration, and restored neuronal integrity (reduced MAP-2
levels). This suggests that HIV replication may directly con-
tribute to the extent of brain pathology in this model. They
also demonstrate that ART consisting of atazanavir, tenofovir,
and emtricitabine was able to effectively penetrate into the
brain within 1 h of injection (Koneru et al. 2014). A significant
decrease, approximately 4-fold, in the numbers of p24+ cells
in treated animals compared with saline-treated mice was ob-
served. The authors conclude that this regimen was insuffi-
cient to eradicate virus from the brain, as p24+ cells were
present in the brains of cART-treated mice; however, animals
were treated for a period of 10 days, a relatively short time.
Nevertheless, this study provides unique information regard-
ing drug penetrance into the brain and demonstrates partial
control of infection in the brains of SCID-HIVE mice on
cART.
PBMC-transplanted NSG mouse model or NSG-huPBL
or Hu-PBMC-NSG The NSG-huPBL model is generated
by intraperitoneal injection of healthy human donor PBMCs
into NSG mice, and systemic distribution of human cells is
observed in these mice (Kim et al. 2016;Wu et al. 2016). After
intraperitoneal exposure to virus, cell-free HIV-RNA and p24
antigen can be detected in the peripheral blood of animals, and
the ratio of CD4+ to CD8+ T cells declines rapidly. HIV-
infected human T cells (p24+/CD3+ dual positive) were pres-
ent in the meninges and cortex of infected animals (Wu et al.
2016). Cell-free HIV-RNA and p24 were detectable in brain
homogenates of infected mice. Microgliosis, astrogliosis, and
neuronal dropout were noted in the brains of mice infected
with HIV-1JR-FL, although this was not noted in mice infected
with HIV-1BJZ57, compared with uninfected controls. The lev-
el of microgliosis observed was correlated with the amount of
p24 present in the brain (Wu et al. 2016). While macrophages
are absent in the brains of huPBL mice, administration of
lipopolysaccharide (LPS) to these mice induces macrophage
trafficking into the CNS (Miura et al. 2003).
Treatment with cART consisting of azidotymidine, indina-
vir, and atazanavir suppressed plasma viremia in HIV-infected
NSG-huPBLmice (Kim et al. 2016). Interruption of treatment
resulted in rebound of virus in the plasma in a group of ani-
mals. Furthermore, treatment with a neutralizing antibody,
068P, prevented the decline in the CD4:CD8 ratio, suggesting
that HIV infection could be inhibited with this antibody (Kim
et al. 2016). However, direct evidence of viral control (p24
production or HIV-RNA levels) was not shown.
CD34-transplanted NSGmouse model or hu-NSG The hu-
NSG model is generated by intravenously or intrahepatically
injecting human CD34+ hematopoietic stem cells, derived
from the cord blood, bone marrow, or fetal liver, into pre-
conditioned NSG mice (Gorantla et al. 2010; Choi et al.
2011; Dash et al. 2011, 2012). In this model, human cells
are present systemically as well as in the CNS, including the
cortex, meninges, and brain stem (Gorantla et al. 2010). As
these animals are reconstituted systemically, they are suscep-
tible to HIV transmission via parenteral routes and support
long-term HIV infection (Denton and Garcia 2011; Krisko
et al. 2013). In hu-NSG mice infected intraperitoneally with
a macrophage-tropic HIV isolate (HIV-1ADA), multi-spliced
and unspliced HIV-RNA was detected by semi-nested qPCR
in the brains of a portion of animals (Arainga et al. 2016).
However, total and integrated DNA levels in the brains of
infected mice were below the limit of detection.
A recent manuscript described a macrophage (Bmature
macrophage^ HLA-DR+/CD14++/CD16+, typically referred
to as intermediate phenotype) reservoir for HIVafter treatment
with long-acting cART (Arainga et al. 2017). In this paper, hu-
NSG mice were infected with HIV-1ADA and were either un-
treated, treated with a 2-drug ART regimen (cabotegravir and
rilpivirine), or a 4-drug ART regimen (cabotegravir,
rilpivirine, lamivudine, and abacavir). Animals were treated
for 4 weeks prior to necropsy. Various T cell populations,
monocytes/macrophages, and CD34 HSCs were sorted from
the blood, spleen, and bone marrow. The frequency of viral
RNA (multi-spliced and unspliced) and viral DNA (total and
integrated) in the sorted monocytes/macrophages (CD14+/
CD16+) was greatest in the spleens of animals treated with
the 4-drug ART regimen (Arainga et al. 2017). This finding
seems unusual as one would expect to find the most virus in
the untreated animals or animals treated with only two drugs.
This could be the result of poor cART penetration or contam-
ination with T cells in the sorted monocyte/macrophage
fraction.
Myeloid-only mouse model The recently described myeloid-
only mouse model, or MoM, is generated by injecting human
hematopoietic stem cells into pre-conditioned NOD/SCID
mice (Honeycutt et al. 2016, 2017). These animals are
reconstituted with human myeloid and B cells and permit for
the systemic analysis of HIV infection in tissue macrophages.
A major benefit of this model is that the presence of virus in
macrophages cannot be attributed to phagocytosis of infected
T cells (Baxter et al. 2014; Calantone et al. 2014). Using flow
cytometry, both classical (CD14+/CD16−) and intermediate
(CD14+/CD16+) macrophages were present in the brains of
MoM.HIV-infected cells were clearly detected in the brains of
infected MoM (Honeycutt et al. 2016). HIV infection was
associated with higher numbers of human hematopoietic cells
and macrophages present in the brain compared with uninfect-
ed controls. Notably, human macrophages were present in the
cerebellum, caudate putamen, cerebral cortex, ventral stria-
tum, and brain stem (Honeycutt et al. 2016). HIV-RNA was
detected by PCR analysis in 57% of samples analyzed, dem-
onstrating that human T cells are not necessary to traffic virus
to or maintain infection in the brain. Further analysis demon-
strated the presence of HIV-infected cells throughout the
brains ofMoM. Regions where HIV p24+ cells were observed
included the cerebellum, cerebral cortex, corpus callosum,
midbrain, brain stem, and caudate putamen (Honeycutt et al.
2016).
While most studies of HIV persistence have focused on T
cells, theMoMmodel offers a unique model to study persistence
exclusively in tissue macrophages. This is critically important
when developing strategies for targeting HIV infection in the
CNS, as the predominant targets for infection of the brain are
myeloid-derived cells such as macrophages and microglia. ART
treatment rapidly reduced the plasma viral load and levels of cell-
associated virus in the tissues of treatedMoM, compared to those
of untreated animals (Honeycutt et al. 2017). The half-life of
infected cells in this model was calculated to be approximately
a day, suggesting that the number of productively infected cells
would decay to approximately 1% after a week of cART treat-
ment (Honeycutt et al. 2017). After cART interruption, re-
establishment of systemic infection was observed in a third of
MoM, and this viral rebound was associated with higher pre-
ART viral burden. This study suggests a role for macrophages
in HIV persistence during treatment and suggests the possibility
that persistent HIV infection of brain myeloid-derived cells could
re-start infection systemically when therapy is removed.
Humanized bone marrow/liver/thymus mouse model
Humanized BLT mice are created by implanting human thy-
mus and liver tissues under the kidney capsule of NSG mice;
these animals are also injected with autologous hematopoietic
stem cells. The result is a robust small animal model that is
reconstituted with a variety of human immune cells including
Tcells, myeloid cells, B cells, and NK cells. These animals are
susceptible to both parenteral and mucosal routes of transmis-
sion (Sun et al. 2007; Denton et al. 2008, 2010). There is no
peer-reviewed publication detailing the characterization of the
brain of this model system. However, some information re-
garding the brains of BLT mice has been reported.
Specifically, human hematopoietic cells are present in the
brains of BLT mice, including T cells, B cells, and myeloid
cells; HIV is detectable in the brains of systemically infected
animals (Brew et al. 2015).
Implementation of cART consisting of tenofovir,
raltegravir, and emtricitabine in HIV-infected BLT mice sup-
presses viremia in the plasma and tissues (Denton et al. 2012,
2014). Latently infected resting CD4+ memory T cells are
present in the BLT mouse model (Denton et al. 2012;
Marsden et al. 2012). Latently infected resting CD4+ T cells
are present at a frequency of about eight infectious units per
million cells in this model (Denton et al. 2012). Rapid viral
rebound is observed in this model after ART interruption. The
BLT mouse model has proved especially useful in the evalu-
ation of latency-reversing agents (LRAs). A combination of
three LRAs (vorinostat, I-BET151, and CTLA-4) in combina-
tion with three antibodies (3BNC117, 10-174, and PG16) was
able to prevent viral rebound in over 50% of HIV-infected
BLT mice. Additionally, two groups have demonstrated that
targeting the interferon response during suppressive cART
treatment restored T cell immune function, reduced size of
the viral reservoir, and delayed viral rebound after ART inter-
ruption (Cheng et al. 2017; Zhen et al. 2017). These results
indicate the potential usefulness of BLT mice for future study
of HIV infection in the CNS.
Humanized Tcell-only mousemodel Implantation of human
thymus and liver tissues under the kidney capsule of NSG
mice leads to systemic reconstitution with human T cells, ex-
clusively (Honeycutt et al. 2013). These T cell-only mice, or
ToM, have been used to study HIV infection in vivo without
contribution from human antigen-presenting cells (Honeycutt
et al. 2013, 2016). T cell-only mice support sustained HIV
replication, and institution of cART in these animals leads to
undetectable plasma viremia over time. More importantly,
analysis of resting memory CD4+ T cells from these mice
demonstrates that latency is established at similar levels to that
present in patients that initiated therapy during the chronic
phase of infection (Honeycutt et al. 2013). Like for BLT mice,
there is no information published as of this date regarding the
repopulation of the brains of ToM with human T cells.
However, if T cells are present in the brains of these animals,
it will allow for the investigation of the role of T cells in HIV
infection and persistence in the CNS.
Strengths and limitations of current humanized
mouse models
One major benefit of using humanized mouse models for HIV
in general, and for studies focusing on the CNS in particular, is
the fact that these animals are highly customizable. Systemic
or local human reconstitution can be achieved with a variety
of cell types, which can shape the types of questions that can
be addressed. In humans, studies are limited to imaging (non-
invasive), cerebral spinal fluid sampling (invasive and not
clear how representative of the brain), and post-mortem anal-
ysis. The use of humanized mice allows for controlled exper-
iments, which can have defined endpoints with whole brain
analysis. Humanized mice are reconstituted with the natural
targets of HIV infection, human T cells, and human myeloid
cells and allow scientists to mimic natural routes of infection
with full-length, replication-competent viruses. By using cells
and/or tissues from a variety of donors in experiments, hu-
manized mice can also represent some of the genetic varia-
tions present in the general population.
The recent observation that macrophages in culture re-
main in a G0-terminally differentiated state, as opposed to
the G1-like state found in tissue macrophages, further
highlights the need for models where human macrophages
can be studied in vivo (Mlcochova et al. 2017). The G1-
like state present in tissue macrophages is thought to al-
low HIV-1 to bypass the replication restriction generally
imposed by SAMHD1, and likely explains how tissue
macrophages are able to sustain HIV replication over time
in vivo (Mlcochova et al. 2017). In this respect, human-
ized mice reconstituted with myeloid cells, including hu-
NSG, huNOG, MoM, and BLT mice, offer a unique ad-
vantage over culture systems.
Each humanized mouse model also has its limitations. For
the SCID-HIVE model, the major limitation is the traumatic
nature of humanization (direct injection into the brain), which
leads to brain pathology even when uninfected cells are used,
although the pathology is more pronounced in HIV-infected
versus that of uninfected cells. Studies in SCID-HIVE mice
have generally been limited to 4 weeks or less as a robust
graft-versus-host disease (GVHD) occurs, which prevents
long-term analysis of HIV persistence in these animals. In
the myeloid-only mouse model, there is a time restraint for
study, as NOD/SCID mice succumb to formation of thymic
lymphomas which are ultimately lethal (generally 9–
14months of age) (Prochazka et al. 1992). However, infection
studies upwards of 22 weeks have been shown in this model
(Honeycutt et al. 2017). In models reconstituted with human
PBMCs, GVHD occurs rapidly and limits the lifespan of the
animals (Ali et al. 2012).
In summary, in all humanized mouse models, the hu-
man immune cells exist in a chimeric environment and
must interact with the endogenous mouse cells .
However, there is a remarkable correspondence between
the human condition and each model is able to recapitu-
late specific key aspects of HIV infection, including
routes of transmission, response to cART, and establish-
ment of viral persistence (Table 1).
Interesting topics for future study
Immune activation in the brains of humanized mice In
response to chronic infection with HIV, a state of persistent
immune activation occurs systemically. In the CNS, this
chronic immune activation can lead to detrimental patholo-
gies. While the robust immune response is extremely benefi-
cial during early/acute infection, long-term chronic inflamma-
tion leads to detrimental effects, including immune exhaustion
(Deeks et al. 2017). By tempering the levels of immune acti-
vation via antagonism of the interferon response in humanized
BLT mice infected with HIV, improved functioning of CD8+
Tcells and a possible decrease in the viral reservoir have been
reported (Cheng et al. 2017; Zhen et al. 2017). Unfortunately,
the CNS was not evaluated in these studies. Several studies in
SCID-HIVE mice have begun to address this phenomenon in
the CNS, including treatment with CEP-1347, B18R, and
ruxolitnib (described earlier). However, it is not clear whether
the pathology observed in the SCID-HIVE model is represen-
tative of the majority of patients in the post-ART era.
Table 1 Comparison of
humanized mouse models for
studies of NeuroHIV and HIV
cure studies
Parameter SCID-HIVE hu-NSG NSG-hu-PBL MoM BLT ToM
Human cells present in CNS Y Y Y Y Ya nd
CNS pathology evaluated Y Y Y Y nd nd
Virus present in CNS Y Y Y Y Ya nd
ART evaluated in CNS Y nd nd nd Ya nd
Human cells present systemically nd Y Y Y Y Y
Susceptible to parenteral HIV
transmission
nd Y Y Y Y Y
Susceptible to mucosal HIV
transmission
nd nd nd nd Y nd
Model for HIV persistence/latency nd Y nd Y Y Y
Y yes, N no, nd not done
a Some information available but lacking primary publication
CD4+ and CD8+ T cell infiltration in the brains of HIV-
infected humanized mice Encephalitis in patients on cART
was associated with infiltration with CD8+ lymphocytes, sug-
gesting these cells may have a role in HAND (Gray et al.
2013). By using systemically reconstituted models, such as
hu-NSG, BLT mice, and T cell-only mice (ToM), it may be
possible to elucidate the underlyingmechanisms driving Tcell
infiltration into the brain. However, this will be dependent on
the integrity of the blood-brain barrier in these models.
Summary
Humanized mouse models reflect key aspects of HIV infec-
tion in patients and provide useful research platforms for
studying infection in vivo. More widespread inclusion of the
CNS into current studies of humanized mouse models, espe-
cially with regard to persistence and eradication studies, will
advance the field considerably. This will be especially impor-
tant in studies using stem cell-transplanted models, which al-
low for prolonged observation (> 20weeks) and could be used
to elucidate the effects of long-term cART on the brain.
Overall, humanized mice have thus far proved to be valuable
in describing the pathogenesis of HIV infection and represent
a potentially useful tool for both NeuroHIV and HIV cure
research.
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